Analysis of the intrahepatic immune landscape in correlation with rising portal hypertension in patients with liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032558

Enrollment

330

Registered

2023-08-25

Start date

2023-10-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis of the liver

Interventions

Group 1: Patients with high-grade liver fibrosis and CSPH Group 2: Patients with high-grade liver fibrosis without CSPH

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients with high-grade liver fibrosis (detected by a liver biopsy or a liver stiffness measurement >15kPa)

Exclusion criteria

Exclusion criteria: Other life-threatening medical conditions, minority, pregnancy, known drug abuse or participation in drug substitution programs, inability to consent. In the prospective part, complications of liver cirrhosis are to be recorded, even if they are life-threatening.

Design outcomes

Primary

Measure	Time frame
IgG Antibodies	—

Secondary

Measure	Time frame
1. intrahepatic T-Cell-Landscape 2. composition of peripheral immune-cells 3. composition of IgG-Antibodies	—

Countries

Germany

Contacts

Public ContactTobias Boettler

Klinik für Innere Medizin II, Uniklinik Freiburg

tobias.boettler@uniklinik-freiburg.de+49 761 270 34043

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026